Proportion of abrasions healed after 24 hours · analgesia in traumatic corneal abrasions
Topical NSAIDs showed no clear difference in proportion of abrasions healed after 24 hours compared with control (low certainty).
1 finding from 1 review
Proportion of abrasions healed after 48 hours · analgesia in traumatic corneal abrasions
Topical NSAIDs showed no clear difference in proportion of abrasions healed after 48 hours compared with control (low certainty).
1 finding from 1 review
Complications of corneal abrasion · analgesia in traumatic corneal abrasions
It is very uncertain whether topical NSAIDs changes complications of corneal abrasion compared with control (very low certainty).
1 finding from 1 review
Adverse drug events · analgesia in traumatic corneal abrasions
It is very uncertain whether topical NSAIDs changes drug‐related adverse events compared with control (very low certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid plus vitamin D leads to higher number of participants achieving 'response' by PGA compared with steroid (high certainty).
1 finding from 1 review
Number of participants achieving 'clearance' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'clearance' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by IGA · scalp psoriasis
Steroid plus vitamin D probably leads to higher number of participants achieving 'response' by IGA compared with steroid (moderate certainty).
1 finding from 1 review
Quality of life · scalp psoriasis
1 finding from 1 review
Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid plus vitamin D showed no clear difference in number of participants withdrawing due to adverse events (AE) compared with steroid (moderate certainty).
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes pain resolution compared with topical ciclosporin (very low certainty).
1 finding from 1 review
Pain (mean VAS score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical clobetasol propionate showed no clear difference in pain (mean VAS score) compared with topical tacrolimus; GRADE not reported.
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes clinical resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes adverse effects compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes clinical resolution compared with topical ciclosporin (very low certainty).
1 finding from 1 review
Pain resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes pain resolution compared with topical tacrolimus (very low certainty).
1 finding from 1 review
Adverse effects · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether topical clobetasol propionate changes adverse effects compared with topical ciclosporin (very low certainty).
1 finding from 1 review